Financial overview of the group
SEK thousand 2020 2019 2020 2019
Oct - Dec Oct - Dec Jan - Dec Jan - Dec
Net sales - - - -
Operating loss -511,573 -244,244 -1,591,279 -739,392
Loss before tax -511,789 -244,400 -1,592,442 -739,920
Loss for the period -512,966 -244,904 -1,594,693 -740,705
Earnings per share before -7.59 -4.42 -25.57 -14.33
and after dilution (SEK)
Cash flow from operating -357,162 -216,974 -1,296,509 -690,566
Cash and cash equivalents 840,255 926,186 840,255 926,186
at the end of the period
Research & development 45% 64% 54% 74%
Conference call for investors, analysts and the media
Year-end Report 2020 and an operational update will be presented by CEO Marty J Duvall and members of Oncopeptides Leadership team, Thursday February 18, 2021 at 14:00 (CET).
The conference call will also be streamed via a link on the website: www.oncopeptides.com.
Phone numbers for participants from:
Sweden: +46 8 566 426 95
Europe: +44 3333 009 030
USA: +1 833 526 83 47
Annual Report 2020: Week starting with April 26, 2021
Interim Report Q1 2021: May 26, 2021
Annual General Meeting 2021: May 26, 2021
Interim Report Q2 2021: August 26, 2021
Interim Report Q3 2021: November 18, 2021
For more information
Marty J Duvall, CEO, Oncopeptides AB (publ)
Linda Holmström, Director of Investor Relations, Oncopeptides AB (publ)
Telephone: +46 (0)708 73 40 95
Rein Piir, Senior Advisor Investor Relations, Oncopeptides AB (publ)
Telephone: +46 (0)70 853 72 92
This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on February 18, 2021.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and releases alkylating agents into tumor cells. Melflufen is in development as a new treatment for the hematological malignancy multiple myeloma and is being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the phase 3 OCEAN study. Based on the results from the HORIZON study a New Drug Application has been submitted to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma. The FDA has granted the New Drug Application a priority review with a PDUFA date of February 28, 2021.Oncopeptides' global Headquarters is in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
More information is available on www.oncopeptides.com.